416 results on '"Akinci, Baris"'
Search Results
2. Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey
3. Impact of lipodystrophy on health-related quality of life: the QuaLip study
4. A rapid action plan to improve diagnosis and management of lipodystrophy syndromes
5. A rapid action plan to improve diagnosis and management of lipodystrophy
6. Management of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical options
7. Loss of thymidine phosphorylase activity disrupts adipocyte differentiation and induces insulin-resistant lipoatrophic diabetes
8. Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip), Pisa, Italy, 28–29 September 2023
9. Complications of lipodystrophy syndromes
10. Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings
11. A cohort analysis of familial partial lipodystrophy from two Mediterranean countries.
12. Lipodystrophy Prevalence, "Lipodystrophy-Like Phenotypes," and Diagnostic Challenges.
13. Unusual Presentations of LMNA-Associated Lipodystrophy with Complex Phenotypes and Generalized Fat Loss: When the Genetic Diagnosis Uncovers Novel Features
14. Metabolic and other morbid complications in congenital generalized lipodystrophy type 4
15. Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency
16. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
17. Deciphering the Clinical Presentations in LMNA-related Lipodystrophy: Report of 115 Cases and a Systematic Review.
18. Deciphering the Clinical Presentations in LMNA-Related Lipodystrophy: Report of 115 cases and a Systematic Review
19. FRI055 LYNC-LD: Prospective Multicenter Natural History Study Of Lipodystrophy Syndromes To Determine Prevalence, Incidence And Predictors Of Diabetes And Severe Hypertriglyceridemia, And Their Complications
20. FRI058 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Metabolic Parameters In Individuals With Generalized Lipodystrophy
21. FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
22. FRI069 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Weight And Associated Comorbidities In Congenital Leptin Deficiency
23. Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study
24. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy
25. Homozygous LMNA p.R582H pathogenic variant reveals increasing effect on the severity of fat loss in lipodystrophy
26. European lipodystrophy registry: background and structure
27. Does the ACR TI-RADS scoring allow us to safely avoid unnecessary thyroid biopsy? single center analysis in a large cohort
28. Clinical features of generalized lipodystrophy in Turkey: a cohort analysis
29. The subtleties of insulin treatment in patients with lipodystrophy
30. Pelvis Magnetic Resonance Imaging to Diagnose Familial Partial Lipodystrophy
31. Partial lipodystrophy of the limbs in a diabetes clinic setting
32. Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4
33. Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities
34. Update on Therapeutic Options in Lipodystrophy
35. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities
36. Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Cambridge, UK, 7–8 April 2022
37. Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid
38. Cardiac phenotype in familial partial lipodystrophy
39. A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature.
40. Management of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical options
41. First metreleptin treatment for generalized lipodystrophy in Turkey
42. The subtleties of insulin treatment in patients with lipodystrophy.
43. Additional file 4 of Loss of thymidine phosphorylase activity disrupts adipocyte differentiation and induces insulin-resistant lipoatrophic diabetes
44. Additional file 3 of Loss of thymidine phosphorylase activity disrupts adipocyte differentiation and induces insulin-resistant lipoatrophic diabetes
45. Additional file 1 of Loss of thymidine phosphorylase activity disrupts adipocyte differentiation and induces insulin-resistant lipoatrophic diabetes
46. Additional file 2 of Loss of thymidine phosphorylase activity disrupts adipocyte differentiation and induces insulin-resistant lipoatrophic diabetes
47. European Consortium of Lipodystrophies Registry, 2022
48. Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome
49. Circulating apelin levels are associated with cardiometabolic risk factors in women with previous gestational diabetes
50. Prediction of developing metabolic syndrome after gestational diabetes mellitus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.